WO2008125259A2 - Super paramagnetic iron oxide nanoparticle coupled tissue soldering - Google Patents
Super paramagnetic iron oxide nanoparticle coupled tissue soldering Download PDFInfo
- Publication number
- WO2008125259A2 WO2008125259A2 PCT/EP2008/002796 EP2008002796W WO2008125259A2 WO 2008125259 A2 WO2008125259 A2 WO 2008125259A2 EP 2008002796 W EP2008002796 W EP 2008002796W WO 2008125259 A2 WO2008125259 A2 WO 2008125259A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- iron oxide
- oxide nanoparticles
- pharmaceutical preparation
- superparamagnetic iron
- tissue
- Prior art date
Links
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 238000005476 soldering Methods 0.000 title claims abstract description 28
- 239000002105 nanoparticle Substances 0.000 title abstract description 22
- 230000004927 fusion Effects 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 37
- 229940031182 nanoparticles iron oxide Drugs 0.000 claims abstract description 29
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 17
- 239000000560 biocompatible material Substances 0.000 claims abstract description 16
- 230000005672 electromagnetic field Effects 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 230000001404 mediated effect Effects 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 3
- -1 poly(ether ester amides Chemical class 0.000 claims description 47
- 229920000642 polymer Polymers 0.000 claims description 17
- 229920001610 polycaprolactone Polymers 0.000 claims description 11
- 239000004632 polycaprolactone Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 8
- 229920000249 biocompatible polymer Polymers 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 7
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 5
- 230000000975 bioactive effect Effects 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 3
- 108010015899 Glycopeptides Proteins 0.000 claims description 3
- 102000002068 Glycopeptides Human genes 0.000 claims description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
- 102000013275 Somatomedins Human genes 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229940105423 erythropoietin Drugs 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 229940053128 nerve growth factor Drugs 0.000 claims description 3
- 230000009278 visceral effect Effects 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 230000002518 glial effect Effects 0.000 claims description 2
- 229910010272 inorganic material Inorganic materials 0.000 claims description 2
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 2
- 229920000128 polypyrrole Polymers 0.000 claims description 2
- 229920000431 shape-memory polymer Polymers 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 1
- 150000002484 inorganic compounds Chemical class 0.000 claims 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims 1
- 229910000679 solder Inorganic materials 0.000 abstract description 25
- 239000000463 material Substances 0.000 abstract description 17
- 210000001519 tissue Anatomy 0.000 description 68
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 33
- 239000002245 particle Substances 0.000 description 26
- 230000006698 induction Effects 0.000 description 21
- 229920001577 copolymer Polymers 0.000 description 20
- 238000010438 heat treatment Methods 0.000 description 15
- 229910052742 iron Inorganic materials 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000004809 Teflon Substances 0.000 description 7
- 229920006362 Teflon® Polymers 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000005291 magnetic effect Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920001451 polypropylene glycol Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 239000003361 porogen Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000975 co-precipitation Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008713 feedback mechanism Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 229920006254 polymer film Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100031939 Erythropoietin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004026 adhesive bonding Methods 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000020169 heat generation Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000000807 solvent casting Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- CKQAOGOZKZJUGA-UHFFFAOYSA-N 1-nonyl-4-(4-nonylphenoxy)benzene Chemical compound C1=CC(CCCCCCCCC)=CC=C1OC1=CC=C(CCCCCCCCC)C=C1 CKQAOGOZKZJUGA-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FOGYNLXERPKEGN-UHFFFAOYSA-N 3-(2-hydroxy-3-methoxyphenyl)-2-[2-methoxy-4-(3-sulfopropyl)phenoxy]propane-1-sulfonic acid Chemical compound COC1=CC=CC(CC(CS(O)(=O)=O)OC=2C(=CC(CCCS(O)(=O)=O)=CC=2)OC)=C1O FOGYNLXERPKEGN-UHFFFAOYSA-N 0.000 description 1
- GDFUWFOCYZZGQU-UHFFFAOYSA-N 4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C=C1 GDFUWFOCYZZGQU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 102000050554 Eph Family Receptors Human genes 0.000 description 1
- 108091008815 Eph receptors Proteins 0.000 description 1
- 229910005335 FePt Inorganic materials 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000482 Poly(bis(4-carboxyphenoxy)phosphazene) Polymers 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229920003060 Poly(vinyl benzyl chloride) Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011127 biaxially oriented polypropylene Substances 0.000 description 1
- 229920006378 biaxially oriented polypropylene Polymers 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000002977 biomimetic material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000005347 demagnetization Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000005674 electromagnetic induction Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 108060002566 ephrin Proteins 0.000 description 1
- 102000012803 ephrin Human genes 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 238000010100 freeform fabrication Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- PWBYYTXZCUZPRD-UHFFFAOYSA-N iron platinum Chemical compound [Fe][Pt][Pt] PWBYYTXZCUZPRD-UHFFFAOYSA-N 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000001725 laser pyrolysis Methods 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 238000012978 minimally invasive surgical procedure Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 102000005162 pleiotrophin Human genes 0.000 description 1
- 229920000075 poly(4-vinylpyridine) Polymers 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002961 polybutylene succinate Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000072 solvent casting and particulate leaching Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920002677 supramolecular polymer Polymers 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 231100000054 whole-body exposure Toxicity 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/02—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
- A61L24/0089—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/02—Oxides; Hydroxides
- C01G49/06—Ferric oxide [Fe2O3]
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G49/00—Compounds of iron
- C01G49/02—Oxides; Hydroxides
- C01G49/08—Ferroso-ferric oxide [Fe3O4]
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1405—Electrodes having a specific shape
- A61B2018/1407—Loop
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/42—Magnetic properties
Definitions
- the present invention relates to the field of sutureless thermal mediated tissue fusion by using superparamagnetic iron oxide nanoparticles (SPIONs) dispersed in or immobilized to a solder interface, for the development of minimally invasive surgical procedures.
- SPIONs superparamagnetic iron oxide nanoparticles
- soldering appears to have the best profile for clinical application. Adding proteins or polymers to the solder has further improved the connective tensile strength of the tissue fusion, but reproducibility remained problematic (Lauto A. et al., Lasers Surg Med 35:140-145, 2004). Described soldering techniques almost unanimously consisted of optical systems, with highly variable heat deposition resulting from the irregularity of laser beam tissue penetration. Furthermore inhomogeneity in solder deposition complicates the regularity of the resulting connective tensile strength. In contrast, electromagnetic induced thermal induction is less susceptible to these parameters and thus seems advantageous for tissue soldering, especially when the electromagnetic source can be applied close to the site of action.
- tissue fusion should result in an immediate connection, responding to the condition required for the respective application. This can be achieved only by using a mediator such as a mechanical connector, biochemical glue or a soldering technique. For all these techniques the balance between strength of the tissue connection and tissue destruction resulting from long term effects, such as fibrosis or intimal hyperplasia in the case of vascular anastomosis need to be determined. Furthermore new techniques for tissue fusion need to compete with the standard of care such as microsurgery using microsutures or newly non-occlusive anastomosis techniques in order to reduce treatment and pathology related morbidity. Therefore all new developments need to consider the integration of minimally invasive techniques such as endoscopic or endovascular assisted methods. Furthermore the transmitting medium needs to be biocompatible or bioresorbable.
- SPIONs Superparamagnetic iron oxide nanoparticles
- thermal decomposition and/or reduction include co-precipitation, thermal decomposition and/or reduction, micelle synthesis, hydrothermal synthesis, and laser pyrolysis techniques.
- Heating physics of the SPIONs is essentially different from previous descriptions of radiofrequency tissue fusion (US 2004/0210282; US 2003/0236518; Flock ST. and Marchitto K.S., Otolaryngol Clin North Am 38:295-305, 2005).
- SPIONs are non-conductive and thus are not electromagnetically inducible.
- the invention relates to superparamagnetic iron oxide nanoparticles for use in sutureless thermal mediated tissue fusion.
- the invention furthermore relates to a pharmaceutical preparation comprising superparamagnetic iron oxide nanoparticles, preferably with a diameter of below 20 nm, and such nanoparticles coated with an organic compound and/or imbedded in a biocompatible material, for example a soldering agent.
- the invention likewise relates to the use of superparamagnetic iron oxide nanoparticles for the manufacture of a medicament for use in tissue fusion with an alternating electromagnetic field, and to a method of tissue fusion wherein superparamagnetic iron oxide nanoparticles dispersed in a biocompatible interface material are heated by application of an alternating electromagnetic field.
- FIG 1 Schematic stimulating setup.
- a high frequency power generator (PG) creates an electromagnetic field, inside a thin water cooled cooper coil (CC).
- a fluoro-optical temperature sensor system is used for temperature feedback (TM) which allows controlling the negative feedback loop by computer steering (CS).
- Figure 2 Haematoxylin and eosin (HE) staining of side to side SPION dispersed albumin soldering of two abdominal rabbit aortas, showing the tight contact of the two layers. Collagen structures are minimally altered.
- Figure 3 Electron micrograph of superparamagnetic iron oxide nanoparticles as they were used for tissue soldering in Figure 2.
- Figure 4 Schematic drawing of nanoparticles coated with polyvinyl-alcohol and proteinous macromolecules bonded to it, for specialized soldering or fixation to a scaffold structure.
- Figure 5 MRI signal decay curve for liver as the region of interest (ROI) of 7 rats (sham, 1d, 3d, 2w, 4w). The slopes of the curves do not significantly differ for rats with implanted film and sham treated rats as well as for different implantation times.
- X-axis represents TE relaxation time and y-axis represents T2-intensity.
- Figure 6 T2w sagittal and axial image showing susceptibility at the soldered site (arrows) 4 days after subcutaneous tissue soldering with SPIONs in the neck of the rat.
- the present invention is directed to the use of superparamagnetic iron oxide nanoparticles (SPIONs) dispersed in biocompatible material to produce tissue fusion by application of an alternating electromagnetic field and thus heat generation.
- SPIONs superparamagnetic iron oxide nanoparticles
- superparamagnetic iron oxide nanoparticles are known and can be obtained by known methods.
- superparamagnetic iron oxide nanoparticles also includes corresponding superparamagnetic nanoparticles obtained from iron-platinum (FePt).
- FePt iron-platinum
- SPIONs of a diameter of below 20 nm, for example between 5 nm and 20 nm, e.g. around 15 nm.
- These nanoparticles may be applied as a dispersion in a biocompatible material, whereby such a dispersion may consist of completely dispersed nanoparticles or may also contain agglomerates comprising a few nanoparticles, e.g.
- a biocompatible material is a material that may be applied to the animal body, in particular to the human body, and is non-toxic, causes no or only limited irritation at the site of application, does not cause a rejection by the animal or human body, and may be temporarily or permanently integrated into structures of the animal or human body.
- biocompatible materials are low molecular weight compounds, e.g. water, solutions of inorganic salts in water, for example physiological saline, aqueous solutions of amino acids and/or sugars, aqueous solutions comprising excipients such as are used for the preparation of injectable pharmaceutical preparations, proteins, peptides and glycopeptides of animal or human origin, and biocompatible polymers.
- Such biocompatible polymers are polystyrenes, for example poly(styrene-co-chloromethyl- sytrene), poly(styrene-co-chloromethylstyrene-co-methyl-4-vinylbenzyl)ether, poly (styrene-co-chloromethylsytrene), their derivatives and copolymers; polyphosphoester, for example poly[1 ,4-bis(hydroxyethyl)terephthalate-co-ethyloxyphosphate], poly((lactide-co- ethyleneglycol)-co-ethyloxyphosphate), poly(1 ,4-bis(hydroxyethyl)terephthalate-co- ethyloxyphosphate), their derivatives and copolymers; polyphosphazenes, for example poly(bis(4-carboxyphenoxy)phosphazene), poly(bis(1-(ethoxycarbonyl)methylamino) phospha
- biocompatible polymers considered are those containing a hydrolyzable backbone, for example poly(amide-enamines), their derivatives and copolymers; poly(anhydrides), for example poly(adipic anhydride), their derivatives and copolymers; natural polymers and polysaccharides, such as cellulose, chitosan, maltodextrin, starch, agar, alginic acids and their copolymers and derivatives; polypeptides, for example gelatin, their derivatives and copolymers, poly(ethylene glycol) (PEG) based polymers, their derivatives and copolymers; polypropylene, its derivatives and copolymers, for example poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol); polyanhydrides, for example (4-carboxyphenoxy)propane, their derivatives and copolymers; polymers with carbon backbones, for example polyvinyl alcohol) and poly(vinylacetate), their derivative
- biocompatible materials are proteins, peptides and glycopeptides of animal or human origin, and biocompatible polymers.
- SPIONs are dispersed in a solder for improvement of tissue fusion.
- a "solder" as understood in the context of the invention is a biocompatible material, for example as described hereinbefore, which assists in gluing tissue when heated.
- the solder may contain small or large molecules suitable for tissue soldering.
- Such molecules are biocompatible proteins, crosslinkers or polymerisates.
- Preferred substances are serum proteins and other proteins present in the animal or human body not having any immunogenic properties, and thus being clinically applicable, for example albumin, fibrin, fibrinogen, myoglobin, and collagen of different types. Particularly preferred is albumin.
- SPIONs may be dispersed in a biocompatible scaffold.
- the scaffold is either of solid, flexible, and/or semi-liquid-state.
- the scaffold may have different porosity. Suitable biocompatible material forming such a scaffold are listed hereinbefore.
- scaffolds comprise polyglycolide, polylactides, polycaprolactone; di- and tri-block polymers, such as polymers incorporating polyethyleneoxides or polycaprolactone, and other resorbable polymers in different chain arrangements which confer both degradation and mechanical property customization; other polymeric biomaterials, such as polyorthoesters, polyanhydrides, polyhydroxy- alkanoates, polypyrroles, poly(ether ester amides), elastic shape-memory polymers; hydrogels; and biomimetic materials, supramolecular polymers formed by self-assembly, and matrices presenting distinctive or a variety of biochemical cues (Polym lnt 56:145- 157, 2007).
- the scaffolds include furthermore foam material that can be stabilized by SPIONs or can contain SPIONs.
- the morphology, magnitude, and interconnection of the scaffolds' porosity are critical factors in assessing their viability as tissue engineering devices (Adv Polym Sci 200:209- 231 , 2006).
- the porosity can be introduced into the scaffolds by methods such as melt extruding methods, solvent casting and particulate leaching methods, phase separation techniques, freeze drying, carbon dioxide foaming, chemical crosslinking of the polymers by crosslinking techniques including as well thermal and photocrosslinking, solid free form fabrication (Adv Biochem Engin/Biotechnol 102:187-238, 2006), wet spinning, electrospinning, or self-assembly techniques.
- sintered materials containing superparamagnetic nanoparticles can be used.
- the solder material can be either incorporated directly in the scaffold material or added subsequently into the pores.
- a further useful method consists of dissolving a polymer without and with nanoparticles in a solvent, and adding particles of a leachable porogen, such as a salt or glucose. The mixture is left to dry in air or in a vacuum until the solvent has evaporated completely. The porogen is then dissolved in a suitable solvent leaving behind a network of interconnected pores. Porosities can be controlled by the size of the porogen (10 ⁇ m to 2 mm) and the weight % of the inserted porogen (10 - 98 wt%).
- Phase separation methods consist of inducing a solid-liquid or liquid-liquid phase separation of the polymer solution.
- the polymer is dissolved in a solvent and quenched at a certain temperature ranging from 0 0 C to -196 0 C.
- the solutions are finally freeze-dried for several days in vacuum.
- microstructured materials can be created. Structures can be controlled by varying certain processing parameters such as the quenching temperature, the freeze-drying temperature, and the polymer concentration (Adv Polym Sci 200: 209-231 , 2006).
- the SPION dispersed scaffold may contain further bioactive molecules enabling a long term stimulative or inhibitory effect on surrounding viable tissue.
- Bioactive molecules may be of enzymatic, hormone, cytoinductive or cytoinhibitory effect.
- Examples of preferred bioactive molecules are vascular endothelial growth factor (VEGF), nerve growth factor (NGF) 1 brain derived neurothropic factor (BDNF), glial derived neurotropic factor (GDNF), erythropoietin (EPO) 1 fibroblast growth factor (FGF), transforming growth factor (TGF), insulin-like growth factor (IGF) 1 and subgroups of the mentioned compounds.
- activins activins, inhibins and receptors, angiogenic factors, chemokines, ephrin and ephrin receptors, epidermal growth factors (EGF) 1 hematopoietic cytokines, hepatocyte growth factor, interferons (IFN), interleukins (IL), neurotrophic factors, oncostatin M (OSM) 1 platelet-derived growth factor (PDGF) and corresponding receptors, pleiotrophin, tumor necrosis factor (TNF), and subgroups of the corresponding families.
- EGF epidermal growth factors
- IFN interferons
- IL interleukins
- OSM oncostatin M
- PDGF platelet-derived growth factor
- TNF tumor necrosis factor
- additives may be added to the solder in order to cause a conformational change resulting in unique properties in conjunction with the nanoparticle tissue fusion by electromagnetic stimulation.
- Such additives may permit a physical conformation change of the solder during the fusion procedure from liquid to solid or from solid to liquid state, or help keep the solder liquid or solid, respectively.
- Additives may, for example, be activated by heat.
- Particular additives considered are acrylates, tensides, inorganic salts, surfactants, lipids and sphingolipids.
- the present invention is directed to the fusion of biological tissue surfaces independent of their nature.
- Particularly preferred biological tissue surfaces are skin, or the surface of musculoskeletal, visceral, vascular, or neuro-glial tissue.
- the tissue is fused using the intermediacy of biocompatible material containing nanoparticles of the invention.
- the strength of fusion may be anywhere from weak to strong, and may be for temporary binding or permanent binding whereby natural tissue replaces the fusion over time.
- SPIONs Superparamagnetic iron oxide nanoparticles
- the present invention is directed to pharmaceutical preparations comprising superparamagnetic iron oxide nanoparticles (SPIONs), in particular such nanoparticles having a diameter of below 20 nm, for example between 5 and 20 nm, such as around 15 nm.
- SPIONs superparamagnetic iron oxide nanoparticles
- the nanoparticle may be used as such or coated with an organic compound, for example coated with a polymer layer.
- This coating material may be further connected to proteins or biocompatible polymers.
- the pharmaceutical preparation may further comprise a biocompatible material as defined hereinbefore, in particular a soldering agent, and other excipients conventionally used in injectable solutions.
- excipients considered are, for example, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes.
- the said solutions or suspensions may comprise viscosity- increasing agents, typically sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, or gelatins, or also solubilizers, e.g. Tween 80 (polyoxy- ethylene(20)sorbitan mono-oleate).
- injectable preparations are usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.
- the present invention uses an electromagnetic wave generator setup including a thermal feedback steering system, for stimulation of superparamagnetic iron oxide nanoparticles (Figure 1).
- the main heating effect in an electromagnetic alternating field is resistive heating caused by magnetically induced currents called eddy currents.
- the heating of the SPIONs as described in this invention is due to Neel relaxation, which occurs in superparamagnetic particles exposed to an alternating magnetic field. The extent of the relaxation mechanism contributing to the heating is dependent on the size of the particle, the frequency, and temperature. Heating of the nanoparticles occurs by Neel relaxation, which itself depends on the volume of the particles and the anisotropic constant. Neel relaxation is caused by the reorientation of the magnetization vector inside the (fixed) magnetic particle against an energy barrier.
- SAR specific absorption rate
- the SAR depends on the applied magnetic field strength (H), the frequency ( ⁇ ), the effective relaxation time which combines the Brownian and Neel relaxation ( ⁇ eff ), the temperature (T) and the volume of the particles (V).
- k B is the Boltzman constant and m the magnetic moment of the particles. Physical limits of the above equation are given by the superparamagnetic limit, which is for iron oxide between room temperature and 10O 0 C at around 20 nm particle diameter. This means that the particle has to be smaller than 20 nm.
- the limit for the maximal frequency is given by the relaxation time which is determined by the volume of the particles and the magnetic exchange energy.
- the diameter of the particles has to be between 10 and 20 nm, preferably between 15 to 20 nm, and the frequency between 1 and 30 MHz, preferably between 20 and 30 MHz.
- the second relaxation mechanism the Brownian relaxation (particles rotate according the applied field) does not contribute to the heating.
- SPIONs may act in agglomerates or as individual particles. In general, with increasing frequency the heat generation increases. This effect is most important around the optimal particle size of around 15 nm.
- the electromagnetic field transmitter device design and power specifications are dependent on the site of the field application in the body (at the surface or deep in the body), site access (wide or narrow), and the necessary SPION dispersed solder interface heating specifications. For example fusion of vascular tissue may necessitate a different solder type and thus SPION dispersion than neuronal, dermal or visceral tissue. A deep seated structure in the depth of a craniotomy gives less freedom of movement than a structure located at the body surface. Thus the design of the transmitter device can vary form slim and long to short and wide.
- the device may be miniaturized and serve in minimally invasive surgery and in endoscopy.
- the device comprises, for example, a fluoro-optical temperature sensor. Other temperature feedback techniques may be used, e.g. a thermocouple, laseroptical or a thermocamera system.
- the transmitter induction properties should demonstrate a clinically suitable time lapse to reach the preferred target temperature of between 4O 0 C and 150 0 C, in particular 8O 0 C ⁇ 5, for surgical reasons such as limited immobilization of the soldering site and the changes in the soldering environment. Furthermore the temperature profile and especially the temperature feedback mechanism should result in minimal fluctuations in the temperature profile. Temperature fluctuations observed are minimal with the SPIONs dispersed in solders. Furthermore SPIONs are homogenously dispersed over the tissue interface, permitting a good temperature feedback control.
- Electromagnetic heating of SPIONs is dependent on the size of the particles and the medium they are dispersed in.
- Conductivity (S/m) is defined as the inverse resistance and describes how much the electromagnetic wave is attenuated as it transits the material.
- Conductivity reduces the electromagnetic radiation penetration into or through material, as the free electrons and ions in the material are moved by the incoming wave's field.
- Conductivity is dependent on the applied frequency and the tissue exposed to the irradiation. For example, the conductivity is expected to be between 0.1 and 1 S/m at the particular exemplified frequency of 1.8 MHz. The conductivity loss over a tissue segment of a thickness between 0.5 to 1 mm is thus negligible in a local applicable induction system.
- the electromagnetic induction power unit used in the exemplification of this invention is designed for fusion of metal parts, the frequency at which the induction is performed (1 -30 MHz) as well as the dimension of the coil and thus the field dimension are not of safety concern for a whole body exposure as well as local close application to biological tissue, as long as not metal parts, or metal dust is involved.
- the SPIONs obtained by the co-precipitation method generally yield individual particles with an average diameter around 10 nm, for example 9 nm. Depending on the measurement technique, size distributions from 5-15 nm (number weighted) are obtained. These individual particles may be coated with synthetic polymers, fatty acids, proteins, carbohydrates, or inorganic materials to yield either individually coated single particles, or agglomerates of the latter. This is influenced by the intrinsic properties (e.g. hydrophilicity, hydrophobicity) of the coating material used.
- silanes such as aminopropyltriethoxysilane (APS), tetramethoxysilane (TMOS), tetraethoxysilane (TEOS), or derivates thereof.
- APS aminopropyltriethoxysilane
- TMOS tetramethoxysilane
- TEOS tetraethoxysilane
- Coating substances considered are, for example, the biocompatible polymers listed hereinbefore, and biocompatible proteins, crosslinkers or molecules enhancing the tissue fusion. These coating substances may be attached directly or through an intermediary functional silane as described hereinbefore.
- Preferred coating substances are serum proteins and other proteins present in the animal or human body not having any immunogenic properties, and thus being clinically applicable, for example albumin, fibrin, fibrinogen, myoglobin, and collagen of different types.
- the particle surfaces can be further functionalized according to standard bioconjugate coupling techniques. Molecules to be coupled to the particles are either directly covalently attached to the SPIONs or via standard cross-linkers.
- the compounds of the invention may not only be used for fusion of biological tissue, but also for fusion of biological tissue to implants.
- the SPION dispersed solder composition optionally comprises additives depending on the implant material to which fusion is required.
- the material used in a vascular graft is typically manufactured from polytetrafluoroethylene (PTFE).
- PTFE polytetrafluoroethylene
- the SPION dispersed fusion composition will then be adapted to preferentially adhere to PTFE.
- the biological tissue is fused to the implanted material, and the implant is thereby sealed and stabilized.
- a particular application is the fusion of a PTFE vessel graft to a blood vessel for bypass surgery.
- Other implantable materials may be on the basis of polygly-co-lactide (PGA-PGLA), or any one of the biocompatible polymers listed hereinbefore.
- SPIONs Superparamagnetic iron oxide nanoparticles
- Superparamagnetic iron oxide nanoparticles are prepared by alkaline co-precipitation of ferric and ferrous chlorides in aqueous solution as described by Chastellain M. et al., J Colloid Interface Sci 278:353-360, 2004.
- the obtained black precipitate is washed several times with ultra-pure water and the remaining solid refluxed in nitric acid (10 '2 M) in the presence of iron-(lll)-nitrate.
- the obtained brown suspension is dialyzed against 0.01 M nitric acid for two days, and stored at 4 0 C.
- SPIONs embedded in BSA SPIONs are concentrated from the original dispersion (10 mg/ml Fe) by different methods.
- SPIONs in scaffolds Polymer film preparation: 15 ml of SPIONs (7.7 mg/ml Fe) are mixed with 7.5 ml of 1 M ammonia (Fluka), 150 ⁇ l oleic acid (Fluka, cat. no. 75093) and 105 ml chloroform (Fluka). The resulting mixture is centrifuged at 3000 g for 10 minutes to transfer the SPIONs into the organic chloroform phase. The water phase is discarded and the particle dispersion concentrated to a final iron concentration of 115 mg/ml (4 ml) under the fume hood.
- Fluka 1 M ammonia
- Fluka 150 ⁇ l oleic acid
- Fluka cat. no. 75093
- Fluka chloroform
- Nonporous films of polycaprolactone containing 5, 10, 20, 30, and 40% (w/w) iron are prepared by using a solvent-casting technique.
- a scaffold containing 40% (w/w) iron 56 mg of polycaprolactone is dissolved in 1 ml of chloroform.
- 466 ⁇ l of the SPION dispersion described above is added and mixed.
- This solution is spread to cover the bottom surface of a 32 mm Petri dish that is cleaned first with chloroform, followed by ethanol, and ultra-filtered deionized water. After air drying (24 h), the films are hydrated for 1 hour and then carefully peeled off the bottom of the Petri dish. Then, the resulting polymer films are air dried and stored at room temperature.
- Porous films of polycaprolactone containing 5, 10, 20, 30, and 40% (w/w) iron are prepared by using a solvent-casting technique and particulate leaching technique.
- a scaffold containing 40% (w/w) iron 56 mg of polycaprolactone is dissolved in 1 ml of chloroform.
- 466 ⁇ l of the SPION dispersion described above is added and mixed.
- sodium chloride particles of a size between 100 and 125 ⁇ m at concentrations of 70 to 90 (w/w) are added, corresponding to 217.7 and 839.3 mg, respectively.
- For scaffolds with lower iron content these values are adapted.
- This solution is spread to cover the bottom surface of a 32 mm Petri dish that is cleaned first with chloroform, followed by ethanol, and ultra-filtered deionized water. After air drying for 24 h, the films are hydrated for 1 hour and then carefully peeled off the bottom of the Petri dish. Then the resulting polymer films are air dried and stored at room temperature.
- Polycaprolactone may also be replaced by poly (DL-lactide-co-caprolactone) 40:60, poly (DL-lactide) and other copolymers.
- a system consisting of a high frequency generator (Power Controller 32/1800, Ceia, Italy) operated at a frequency of 1.8 MHz and a magnetic flux density of 40 mT is used.
- the generator is connected to a control unit (Power controller v2, Ceia, Italy), which sets the energy output of the system at a predefined optimum for the special coil.
- the alternating current is transferred on a water cooled coil consisting of a thin copper tube which induces the electromagnetic field. This coil has an outer diameter of 5.5 mm, the tube itself has a diameter of 1.5 mm. Cooling is achieved by continuous water flow through the tube.
- the output power is controlled by reduction of the pulse length of the electromagnetic field for lower power levels or by changing the strengths of the electromagnetic field by changing the current.
- a second and custom made induction device consisting of a frequency generator, an amplifier and a resonant circuit harbouring a ferrite core has been realized.
- the resonant circuit is justified for maximal energy absorption in the tissue.
- the operating frequency is adaptable from 30 kHz to 470 MHz, and the amplifier power is 2000 W.
- a fluoro-optical temperature sensor (FOT Lab-Kit, Luxtron, CA, USA) is used, allowing the recording of a contact temperature profile at a pickup frequency of 4 Hz.
- a negative feedback control consisting of a control unit (Power controller v2, Ceia, Italy) between the temperature measurement system and the high frequency generator enables a fast and constant levelling of the temperature (Figure 1).
- a platinum ring (MR) (inner diameter: 2.8 mm, wire diameter: 0.25 mm) (ELANA BV, Utrecht, The Netherlands) and a stainless steel grid (MG) (BOPP, Zurich, Switzerland) with a wire diameter: 0.065 mm, mesh opening: 0.3 mm are used as solid mediators for conversion of the electromagnetic to thermal energy and are compared with dispersed agglomerates of SPION with particles size of 15 nm in diameter.
- Solder Solder consists of 36% (w/w) of bovine serum albumin (BSA) dissolved in pure sterile water for the experiments in conjunction with the solid metal parts (MR and MG). BSA concentration is kept at 20% (w/w) in combination with SPIONs.
- BSA bovine serum albumin
- Teflon receptacle A teflon receptacle is used for the analysis of the temperature profiles for MR and
- the distance from the induction coil to MR and MG is between 1.2 mm and 2.4 mm and for the SPIONs 2.4 mm defined as the distance from the centre of the measured volume (30 ⁇ l) in the receptacle to the coil.
- the total induction time is dependent on the time needed to reach the target temperature of 8O 0 C ⁇ 5 0 C and the holding time.
- a tissue soldering holding time of 60 seconds is considered suitable for tissue fusion.
- Pieces of rabbit abdominal aorta (15 x 10 mm) are used for the in vitro soldering experiments (Soltermann, Th ⁇ rigen, Switzerland). The two adventitial surfaces are soldered together with an overlapping area of 1 cm 2 responsible for the connection.
- the tissue is placed in a custom made tissue holder made out of Perspex, enabling a constant distance of the tissue and the induction coil.
- the strength of the so induced tissue connection is quantified using a tensile strength measurement setup. Both pieces of soldered tissue are fixed with surgical clamps, one of them attached to a force gauge measuring the maximum tensile strength in mN during the rupture procedure.
- the heating of the MR in 30 ⁇ l of albumin solder in the teflon receptacle is tested. Temperature heating curves are analyzed in dependence of power output and distance of the induction coil to the metal parts. A maximum temperature of 100 0 C is reached. Induction time is 30 s. Solder temperatures increased in dependence of power and distance during the 30 s induction time.
- the optimal distance for induction of the MR for tissue fusion is found to be in the range of 2 to 4 mm.
- the optimal range for power is found to be between 20 and 50%, always dependent on distance (distance 4 mm: 50% power, distance 2 mm: 20% power).
- Pieces of vascular tissue are adapted as described above. Between the two tissue pieces a MR as well as 30 ⁇ l of BSA solder without and with an oxidized cellulose gauze (Tabotamp, Johnson and Johnson, Switzerland) is placed. This complex is exposed to the electromagnetic field for soldering. The grid is immersed in 30 ⁇ l of solder before placing it between the two tissue pieces. Temperature is regulated with the above described feedback mechanism at 80 0 C. Induction time is 60 s after reaching 80"C. In order to maintain this temperature over 60 seconds, the power of the electromagnetic high frequency generator is regulated by the temperature control feedback to a mean power output of 20%.
- Pieces of vascular tissue are adapted as described above. 30 ⁇ l of SPION (20% w/w) dispersed in BSA are used.
- the induction setup needs to be adapted in order to reach sufficient induction parameters to reach the acceptable temperatures. Temperature is regulated with the above described feedback mechanism at 8O 0 C. Induction time is 60 s after reaching 80 °C.
- the power of the electromagnetic high frequency generator is set at 90%, according to the findings from the teflon receptacle studies. Tissue soldering compared with suturing
- a (8-0) Prolene thread (Ethicon J&J, Spreitenbach, Switzerland) was used to accomplish interrupted suture, seven stitches were performed along the tissue edge of 1 cm. Thereafter, tensile strength of these samples were measured, too, yielding a rupture force of 2580 ⁇ 950 nM.
- Soldered tissue is fixated in formaldehyde and later embedded into methylacrylate resin over a 30 day period for slow hardening in order to perform the tissue slices.
- the tissue blocks are then cut with a diamond band saw with a slice thickness of 150 ⁇ m (Exakt Apparatebau, Nordersted-Hamburg, Germany). Thereafter the slices are polished down to a thickness of 50 ⁇ m.
- the slices are stained using haematoxylin and eosin (HE).
- HE haematoxylin and eosin
- the histological HE staining of the electromagnetically induced vessel tissue fusion using SPION demonstrates the close contact of the abdominal aorta vessel tissue pieces ( Figure 2).
- Subcutaneous implantation of SPION-BSA-PVA solder into 10 living rats is performed in order to observe eventual pathologic effects on the living body, such as those observed in the iron storage disease called haemochromatosis.
- This hereditary disease is characterized by improper dietary iron metabolism (making it an iron overload disorder), which causes the accumulation of iron in a number of body such as liver, kidney and pancreas. Since nanoparticles are theoretically small enough to pass the blood-brain barrier, the brain is also investigated to achieve certainty that it is not affected.
- MRI is performed on the rats, and iron presence is checked in the regions of interest as a mean to measure iron content variations.
- the rats are euthanized right after MRI and histology is performed on the organs of interest. This enables a control of the measured T2 * relaxation times (MRI).
- MRI magnetic resonance imaging
- the resulting tissue iron content correlates with microscopical analyses of particular organs by special iron stainings. Further information is collected about the behaviour of the film in living tissue. In order to find out how the surrounding tissue reacts to the implant, histology is performed on the implantation region.
- Solder film composition was 25 % (w/w) SPION, 42 % (w/w) BSA and 8 % (w/w) water. Sample dimensions were 5 mm x 5 mm x 0.5 mm. Films were implanted subcutaneously into the neck of 8 rats; 4 of the films were then electromagnetically soldered, while 4 of them were kept in their raw state. MRI and euthanization was performed after 1 , 4, 15 and 28 days. MRI was done on one sham rat, and histology was made on two sham rats as well as on all other rats. Figure 5 shows that there are no significant changes in the presence of the SPION-BSA- PVA implant in the liver, spleen, kidney, brain and pancreas by MRI.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Composite Materials (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Power Engineering (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to superparamagnetic iron oxide nanoparticles for use in sutureless thermal mediated tissue fusion. The nanoparticles are dispersed in a biocompatible solder material and heated by application of an alternating electromagnetic field. The invention furthermore relates to a pharmaceutical preparation comprising superparamagnetic iron oxide nanoparticles, preferably with a diameter of below 20 nm, and such nanoparticles coated with an organic compound and/or imbedded in a biocompatible material, for example a soldering agent. The invention likewise relates to the use of superparamagnetic iron oxide nanoparticles for the manufacture of a medicament for use in tissue fusion with an alternating electromagnetic field, and to a method of tissue fusion wherein superparamagnetic iron oxide nanoparticles dispersed in a biocompatible interface material are heated by application of an alternating electromagnetic field.
Description
Super paramagnetic iron oxide nanoparticle coupled tissue soldering
Field of the invention
The present invention relates to the field of sutureless thermal mediated tissue fusion by using superparamagnetic iron oxide nanoparticles (SPIONs) dispersed in or immobilized to a solder interface, for the development of minimally invasive surgical procedures.
Background of the invention
Minimizing tissue injury has been a key interest ever since surgery has been performed. Development of micro-optics has permitted a constant improvement towards minimally invasive and endoscopic approaches (Quayle S. S. et al., Urology 66:489-493, 2005). For endovascular procedures the point of interest is remote to the point of entry. Parallel to these developments, the underlying treatment of the pathology needs to be addressed specifically, hence miniaturized and elaborated, such as by using sutureless tissue fusion techniques. Research in these directions was emphasized over the last three decades, focusing on either a micromechanical, gluing or soldering technique (Constantinescu M.A. et al., Lasers Med Sci 22:10-14, 2007). From these three techniques, soldering appears to have the best profile for clinical application. Adding proteins or polymers to the solder has further improved the connective tensile strength of the tissue fusion, but reproducibility remained problematic (Lauto A. et al., Lasers Surg Med 35:140-145, 2004). Described soldering techniques almost unanimously consisted of optical systems, with highly variable heat deposition resulting from the irregularity of laser beam tissue penetration. Furthermore inhomogeneity in solder deposition complicates the regularity of the resulting connective tensile strength. In contrast, electromagnetic induced thermal induction is less susceptible to these parameters and thus seems advantageous for tissue soldering, especially when the electromagnetic source can be applied close to the site of action.
Techniques for tissue fusion should result in an immediate connection, responding to the condition required for the respective application. This can be achieved only by using a mediator such as a mechanical connector, biochemical glue or a soldering technique. For all these techniques the balance between strength of the tissue connection and tissue destruction resulting from long term effects, such as fibrosis or intimal hyperplasia in the case of vascular anastomosis need to be determined. Furthermore new techniques for tissue fusion need to compete with the standard of care such as microsurgery using
microsutures or newly non-occlusive anastomosis techniques in order to reduce treatment and pathology related morbidity. Therefore all new developments need to consider the integration of minimally invasive techniques such as endoscopic or endovascular assisted methods. Furthermore the transmitting medium needs to be biocompatible or bioresorbable.
Superparamagnetic iron oxide nanoparticles (SPIONs) are obtainable by many different methods, including co-precipitation, thermal decomposition and/or reduction, micelle synthesis, hydrothermal synthesis, and laser pyrolysis techniques (Lu A.H. et al., Angew Chem lnt Ed 46:1222-1244, 2007). Heating physics of the SPIONs is essentially different from previous descriptions of radiofrequency tissue fusion (US 2004/0210282; US 2003/0236518; Flock ST. and Marchitto K.S., Otolaryngol Clin North Am 38:295-305, 2005). SPIONs are non-conductive and thus are not electromagnetically inducible.
Summary of the invention
The invention relates to superparamagnetic iron oxide nanoparticles for use in sutureless thermal mediated tissue fusion. The invention furthermore relates to a pharmaceutical preparation comprising superparamagnetic iron oxide nanoparticles, preferably with a diameter of below 20 nm, and such nanoparticles coated with an organic compound and/or imbedded in a biocompatible material, for example a soldering agent.
The invention likewise relates to the use of superparamagnetic iron oxide nanoparticles for the manufacture of a medicament for use in tissue fusion with an alternating electromagnetic field, and to a method of tissue fusion wherein superparamagnetic iron oxide nanoparticles dispersed in a biocompatible interface material are heated by application of an alternating electromagnetic field.
Brief description of the figures
Figure 1: Schematic stimulating setup. A high frequency power generator (PG) creates an electromagnetic field, inside a thin water cooled cooper coil (CC). A fluoro-optical temperature sensor system is used for temperature feedback (TM) which allows controlling the negative feedback loop by computer steering (CS). Electromagnetic tissue fusion site (B).
Figure 2: Haematoxylin and eosin (HE) staining of side to side SPION dispersed albumin soldering of two abdominal rabbit aortas, showing the tight contact of the two layers. Collagen structures are minimally altered.
Figure 3: Electron micrograph of superparamagnetic iron oxide nanoparticles as they were used for tissue soldering in Figure 2.
Figure 4: Schematic drawing of nanoparticles coated with polyvinyl-alcohol and proteinous macromolecules bonded to it, for specialized soldering or fixation to a scaffold structure.
Figure 5: MRI signal decay curve for liver as the region of interest (ROI) of 7 rats (sham, 1d, 3d, 2w, 4w). The slopes of the curves do not significantly differ for rats with implanted film and sham treated rats as well as for different implantation times. X-axis represents TE relaxation time and y-axis represents T2-intensity.
Figure 6: T2w sagittal and axial image showing susceptibility at the soldered site (arrows) 4 days after subcutaneous tissue soldering with SPIONs in the neck of the rat.
Detailed description of the invention
The present invention is directed to the use of superparamagnetic iron oxide nanoparticles (SPIONs) dispersed in biocompatible material to produce tissue fusion by application of an alternating electromagnetic field and thus heat generation. The invention as described herein offers a solution to the problem of tissue fusion and responds to the needs of the skilled person in the art.
Superparamagnetic iron oxide nanoparticles are known and can be obtained by known methods. As used herein, superparamagnetic iron oxide nanoparticles also includes corresponding superparamagnetic nanoparticles obtained from iron-platinum (FePt). Of particular use in the method of the invention are SPIONs of a diameter of below 20 nm, for example between 5 nm and 20 nm, e.g. around 15 nm. These nanoparticles may be applied as a dispersion in a biocompatible material, whereby such a dispersion may consist of completely dispersed nanoparticles or may also contain agglomerates comprising a few nanoparticles, e.g. agglomerates of 2 to 50, or preferably 2 to 20, nanoparticles.
A biocompatible material is a material that may be applied to the animal body, in particular to the human body, and is non-toxic, causes no or only limited irritation at the site of application, does not cause a rejection by the animal or human body, and may be temporarily or permanently integrated into structures of the animal or human body.
Examples of biocompatible materials are low molecular weight compounds, e.g. water, solutions of inorganic salts in water, for example physiological saline, aqueous solutions of amino acids and/or sugars, aqueous solutions comprising excipients such as are used for the preparation of injectable pharmaceutical preparations, proteins, peptides and glycopeptides of animal or human origin, and biocompatible polymers.
Such biocompatible polymers are polystyrenes, for example poly(styrene-co-chloromethyl- sytrene), poly(styrene-co-chloromethylstyrene-co-methyl-4-vinylbenzyl)ether, poly (styrene-co-chloromethylsytrene), their derivatives and copolymers; polyphosphoester, for example poly[1 ,4-bis(hydroxyethyl)terephthalate-co-ethyloxyphosphate], poly((lactide-co- ethyleneglycol)-co-ethyloxyphosphate), poly(1 ,4-bis(hydroxyethyl)terephthalate-co- ethyloxyphosphate), their derivatives and copolymers; polyphosphazenes, for example poly(bis(4-carboxyphenoxy)phosphazene), poly(bis(1-(ethoxycarbonyl)methylamino) phosphazene), poly(bis(1-(ethoxycarbonyl)-2-phenylethyl)phosphazene), their derivatives and copolymers; aliphatic polyesters, for example polylactide (PLA), polyglycolide (PGA), polycaprolactone (PCL), and their copolymers, for example poly(lactide-co-caprolactone); polyhydroxybutyric acid (PHB), polyhydroxyvaleric acid (PHV), and their copolymers, for example poly(hydroxybutyric acid-co-hydroxyvaleric acid), their derivatives and copolymers; polybutylene succinates, their derivatives and copolymers.
Further biocompatible polymers considered are those containing a hydrolyzable backbone, for example poly(amide-enamines), their derivatives and copolymers; poly(anhydrides), for example poly(adipic anhydride), their derivatives and copolymers; natural polymers and polysaccharides, such as cellulose, chitosan, maltodextrin, starch, agar, alginic acids and their copolymers and derivatives; polypeptides, for example gelatin, their derivatives and copolymers, poly(ethylene glycol) (PEG) based polymers, their derivatives and copolymers; polypropylene, its derivatives and copolymers, for example poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol); polyanhydrides, for example (4-carboxyphenoxy)propane, their derivatives and copolymers; polymers with carbon backbones, for example polyvinyl alcohol) and poly(vinylacetate), their derivatives and copolymers; dendrimers, for example, PAMAM
dendrimers, cyclotriphosphazene-PMMH-6 dendrimer, PAMAM-OS-trimethoxysilyl dendrimer, their copolymers and derivatives; hydrogels and crosslinked polymers, for example poly(acrylic acid-co-acrylamide), poly(isobutylene-co-maleic acid), poly (isobutylene-co-maleic acid), poly(N-isopropylacrylamide), poly (isobutylene-co-maleic acid), poly(acrylic acid), and their derivatives; hydrophilic polymers, for example lignosulfonic acid, polyacrylamide, polyacrylic acid, poly(acrylonitrile), poly(allylamine), poly(isobutylene), poly(4-vinylpyridine), polyvinylpyrrolidone, their derivatives and copolymers; hydrophobic polymers, for example cucurbit[x]uril, polyacrylonitrile poly (1-decene-sulfone), poly(2-ethylacrylic acid), poly(i-hexadecene-sulfone), poly(ethylene terephthalate), poly(hexafluoropropylene oxide), poly(i -hexene-sulfone), poly(methyl vinyl ether), poly(i -octene-sulfone), poly(propylene glycol), poly(propylene glycol) diglycidyl ether, poly(propylene glycol) methacrylate, poly (propylene glycol) monobutyl ether, poly(propylene glycol) 4-nonylphenyl ether, poly(i -tetradecene-sulfone), poly(tetra- hydrofuran), poly(vinylbenzyl chloride), polyvinyl chloride, poly(4-vinylphenol), poly (4-vinylpyridine-co-styrene), their derivatives and copolymers; polyaminoacids, for example polylysine, their derivatives and copolymers; polycarbonates, polysulfones, polymethacrylate, and salts of these mentioned polymers.
Preferred biocompatible materials are proteins, peptides and glycopeptides of animal or human origin, and biocompatible polymers.
SPIONs are dispersed in a solder for improvement of tissue fusion. A "solder" as understood in the context of the invention is a biocompatible material, for example as described hereinbefore, which assists in gluing tissue when heated. The solder may contain small or large molecules suitable for tissue soldering. Such molecules are biocompatible proteins, crosslinkers or polymerisates. Preferred substances are serum proteins and other proteins present in the animal or human body not having any immunogenic properties, and thus being clinically applicable, for example albumin, fibrin, fibrinogen, myoglobin, and collagen of different types. Particularly preferred is albumin.
SPIONs may be dispersed in a biocompatible scaffold. The scaffold is either of solid, flexible, and/or semi-liquid-state. The scaffold may have different porosity. Suitable biocompatible material forming such a scaffold are listed hereinbefore.
Common clinically established polymers preferred as scaffolds comprise polyglycolide, polylactides, polycaprolactone; di- and tri-block polymers, such as polymers incorporating
polyethyleneoxides or polycaprolactone, and other resorbable polymers in different chain arrangements which confer both degradation and mechanical property customization; other polymeric biomaterials, such as polyorthoesters, polyanhydrides, polyhydroxy- alkanoates, polypyrroles, poly(ether ester amides), elastic shape-memory polymers; hydrogels; and biomimetic materials, supramolecular polymers formed by self-assembly, and matrices presenting distinctive or a variety of biochemical cues (Polym lnt 56:145- 157, 2007). The scaffolds include furthermore foam material that can be stabilized by SPIONs or can contain SPIONs.
The morphology, magnitude, and interconnection of the scaffolds' porosity are critical factors in assessing their viability as tissue engineering devices (Adv Polym Sci 200:209- 231 , 2006). The porosity can be introduced into the scaffolds by methods such as melt extruding methods, solvent casting and particulate leaching methods, phase separation techniques, freeze drying, carbon dioxide foaming, chemical crosslinking of the polymers by crosslinking techniques including as well thermal and photocrosslinking, solid free form fabrication (Adv Biochem Engin/Biotechnol 102:187-238, 2006), wet spinning, electrospinning, or self-assembly techniques. Likewise sintered materials containing superparamagnetic nanoparticles can be used. The solder material can be either incorporated directly in the scaffold material or added subsequently into the pores. A further useful method consists of dissolving a polymer without and with nanoparticles in a solvent, and adding particles of a leachable porogen, such as a salt or glucose. The mixture is left to dry in air or in a vacuum until the solvent has evaporated completely. The porogen is then dissolved in a suitable solvent leaving behind a network of interconnected pores. Porosities can be controlled by the size of the porogen (10 μm to 2 mm) and the weight % of the inserted porogen (10 - 98 wt%). Phase separation methods consist of inducing a solid-liquid or liquid-liquid phase separation of the polymer solution. The polymer is dissolved in a solvent and quenched at a certain temperature ranging from 00C to -1960C. The solutions are finally freeze-dried for several days in vacuum. With this method microstructured materials can be created. Structures can be controlled by varying certain processing parameters such as the quenching temperature, the freeze-drying temperature, and the polymer concentration (Adv Polym Sci 200: 209-231 , 2006).
The SPION dispersed scaffold may contain further bioactive molecules enabling a long term stimulative or inhibitory effect on surrounding viable tissue. Bioactive molecules may be of enzymatic, hormone, cytoinductive or cytoinhibitory effect. Examples of preferred bioactive molecules are vascular endothelial growth factor (VEGF), nerve growth factor
(NGF)1 brain derived neurothropic factor (BDNF), glial derived neurotropic factor (GDNF), erythropoietin (EPO)1 fibroblast growth factor (FGF), transforming growth factor (TGF), insulin-like growth factor (IGF)1 and subgroups of the mentioned compounds.
Further stimulative or inhibitory molecules considered are activins, inhibins and receptors, angiogenic factors, chemokines, ephrin and ephrin receptors, epidermal growth factors (EGF)1 hematopoietic cytokines, hepatocyte growth factor, interferons (IFN), interleukins (IL), neurotrophic factors, oncostatin M (OSM)1 platelet-derived growth factor (PDGF) and corresponding receptors, pleiotrophin, tumor necrosis factor (TNF), and subgroups of the corresponding families.
Further substrates or organic or inorganic additives may be added to the solder in order to cause a conformational change resulting in unique properties in conjunction with the nanoparticle tissue fusion by electromagnetic stimulation. Such additives may permit a physical conformation change of the solder during the fusion procedure from liquid to solid or from solid to liquid state, or help keep the solder liquid or solid, respectively. Additives may, for example, be activated by heat. Particular additives considered are acrylates, tensides, inorganic salts, surfactants, lipids and sphingolipids.
The present invention is directed to the fusion of biological tissue surfaces independent of their nature. Particularly preferred biological tissue surfaces are skin, or the surface of musculoskeletal, visceral, vascular, or neuro-glial tissue. The tissue is fused using the intermediacy of biocompatible material containing nanoparticles of the invention. The strength of fusion may be anywhere from weak to strong, and may be for temporary binding or permanent binding whereby natural tissue replaces the fusion over time.
Superparamagnetic iron oxide nanoparticles (SPIONs) are bioresorbable and are known to be eliminated by macrophages of the mononuclear phagocytosis system.
The present invention is directed to pharmaceutical preparations comprising superparamagnetic iron oxide nanoparticles (SPIONs), in particular such nanoparticles having a diameter of below 20 nm, for example between 5 and 20 nm, such as around 15 nm. The nanoparticle may be used as such or coated with an organic compound, for example coated with a polymer layer. This coating material may be further connected to proteins or biocompatible polymers. The pharmaceutical preparation may further comprise a
biocompatible material as defined hereinbefore, in particular a soldering agent, and other excipients conventionally used in injectable solutions.
Such excipients considered are, for example, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers and are prepared in a manner known per se, for example by means of conventional dissolving and lyophilizing processes. The said solutions or suspensions may comprise viscosity- increasing agents, typically sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, or gelatins, or also solubilizers, e.g. Tween 80 (polyoxy- ethylene(20)sorbitan mono-oleate).
The manufacture of injectable preparations is usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.
The present invention uses an electromagnetic wave generator setup including a thermal feedback steering system, for stimulation of superparamagnetic iron oxide nanoparticles (Figure 1).
In electrically conductive metal parts the main heating effect in an electromagnetic alternating field is resistive heating caused by magnetically induced currents called eddy currents. The heating of the SPIONs as described in this invention is due to Neel relaxation, which occurs in superparamagnetic particles exposed to an alternating magnetic field. The extent of the relaxation mechanism contributing to the heating is dependent on the size of the particle, the frequency, and temperature. Heating of the nanoparticles occurs by Neel relaxation, which itself depends on the volume of the particles and the anisotropic constant. Neel relaxation is caused by the reorientation of the magnetization vector inside the (fixed) magnetic particle against an energy barrier. Each magnetization and demagnetization of the superparamagnetic particles leads to the dissipation of heat, which can be increased by increasing the applied frequency. The specific absorption rate (SAR) quantifies the rate of energy deposition in tissue in hyperthermia, which is a measure of the amount of energy converted by the magnetic particles from the magnetic field into heat per unit time and mass. Usually SAR is described by power losses due to Brownian and Neel relaxation mechanisms:
(m//ωrcπT
P =
2τcirkn TV{ l + ω2τltt)
The SAR depends on the applied magnetic field strength (H), the frequency (ω), the effective relaxation time which combines the Brownian and Neel relaxation (τeff), the temperature (T) and the volume of the particles (V). kB is the Boltzman constant and m the magnetic moment of the particles. Physical limits of the above equation are given by the superparamagnetic limit, which is for iron oxide between room temperature and 10O0C at around 20 nm particle diameter. This means that the particle has to be smaller than 20 nm. The limit for the maximal frequency is given by the relaxation time which is determined by the volume of the particles and the magnetic exchange energy. For a typical heating application the diameter of the particles has to be between 10 and 20 nm, preferably between 15 to 20 nm, and the frequency between 1 and 30 MHz, preferably between 20 and 30 MHz. At these high frequencies, the second relaxation mechanism, the Brownian relaxation (particles rotate according the applied field) does not contribute to the heating.
SPIONs may act in agglomerates or as individual particles. In general, with increasing frequency the heat generation increases. This effect is most important around the optimal particle size of around 15 nm.
The electromagnetic field transmitter device design and power specifications are dependent on the site of the field application in the body (at the surface or deep in the body), site access (wide or narrow), and the necessary SPION dispersed solder interface heating specifications. For example fusion of vascular tissue may necessitate a different solder type and thus SPION dispersion than neuronal, dermal or visceral tissue. A deep seated structure in the depth of a craniotomy gives less freedom of movement than a structure located at the body surface. Thus the design of the transmitter device can vary form slim and long to short and wide. The device may be miniaturized and serve in minimally invasive surgery and in endoscopy. The device comprises, for example, a fluoro-optical temperature sensor. Other temperature feedback techniques may be used, e.g. a thermocouple, laseroptical or a thermocamera system.
Locally applied electromagnetic stimulation results in heating of the SPIONs and the biocompatible material comprising the SPIONs in dispersed form. This leads to fusion of the tissue in contact.
The transmitter induction properties should demonstrate a clinically suitable time lapse to reach the preferred target temperature of between 4O0C and 1500C, in particular 8O0C ± 5,
for surgical reasons such as limited immobilization of the soldering site and the changes in the soldering environment. Furthermore the temperature profile and especially the temperature feedback mechanism should result in minimal fluctuations in the temperature profile. Temperature fluctuations observed are minimal with the SPIONs dispersed in solders. Furthermore SPIONs are homogenously dispersed over the tissue interface, permitting a good temperature feedback control.
Electromagnetic heating of SPIONs is dependent on the size of the particles and the medium they are dispersed in. Conductivity (S/m) is defined as the inverse resistance and describes how much the electromagnetic wave is attenuated as it transits the material. Conductivity reduces the electromagnetic radiation penetration into or through material, as the free electrons and ions in the material are moved by the incoming wave's field. Conductivity is dependent on the applied frequency and the tissue exposed to the irradiation. For example, the conductivity is expected to be between 0.1 and 1 S/m at the particular exemplified frequency of 1.8 MHz. The conductivity loss over a tissue segment of a thickness between 0.5 to 1 mm is thus negligible in a local applicable induction system.
The IEC guidelines recommend not exposing human whole body to more than 4 W/kg in a high frequency field, and the electromagnetic field produced by local transmitters such as cellular phones (900-1800MHz) is controversially discussed. Although the electromagnetic induction power unit used in the exemplification of this invention is designed for fusion of metal parts, the frequency at which the induction is performed (1 -30 MHz) as well as the dimension of the coil and thus the field dimension are not of safety concern for a whole body exposure as well as local close application to biological tissue, as long as not metal parts, or metal dust is involved.
The SPIONs obtained by the co-precipitation method generally yield individual particles with an average diameter around 10 nm, for example 9 nm. Depending on the measurement technique, size distributions from 5-15 nm (number weighted) are obtained. These individual particles may be coated with synthetic polymers, fatty acids, proteins, carbohydrates, or inorganic materials to yield either individually coated single particles, or agglomerates of the latter. This is influenced by the intrinsic properties (e.g. hydrophilicity, hydrophobicity) of the coating material used. While, for example, polymer chains adsorb on the surface of the nanoparticles, covalent coupling to the oxidic surface is achieved
using silanes such as aminopropyltriethoxysilane (APS), tetramethoxysilane (TMOS), tetraethoxysilane (TEOS), or derivates thereof.
Coating substances considered are, for example, the biocompatible polymers listed hereinbefore, and biocompatible proteins, crosslinkers or molecules enhancing the tissue fusion. These coating substances may be attached directly or through an intermediary functional silane as described hereinbefore. Preferred coating substances are serum proteins and other proteins present in the animal or human body not having any immunogenic properties, and thus being clinically applicable, for example albumin, fibrin, fibrinogen, myoglobin, and collagen of different types. The particle surfaces can be further functionalized according to standard bioconjugate coupling techniques. Molecules to be coupled to the particles are either directly covalently attached to the SPIONs or via standard cross-linkers. The chemistry of reactive groups is well known and depends on two interrelated chemical reactions: the reactive functional groups present on the various cross-linking or derivatizing reagents and the functional groups present on the target macromolecules to be modified. An example of a polymer coated nanoparticle linked to further peptides is shown schematically in Figure 4.
The compounds of the invention may not only be used for fusion of biological tissue, but also for fusion of biological tissue to implants. For that purpose, the SPION dispersed solder composition optionally comprises additives depending on the implant material to which fusion is required. For example, the material used in a vascular graft is typically manufactured from polytetrafluoroethylene (PTFE). The SPION dispersed fusion composition will then be adapted to preferentially adhere to PTFE. As a result, the biological tissue is fused to the implanted material, and the implant is thereby sealed and stabilized. A particular application is the fusion of a PTFE vessel graft to a blood vessel for bypass surgery. Other implantable materials may be on the basis of polygly-co-lactide (PGA-PGLA), or any one of the biocompatible polymers listed hereinbefore.
Experimental part
Superparamagnetic iron oxide nanoparticles (SPIONs)
Superparamagnetic iron oxide nanoparticles are prepared by alkaline co-precipitation of ferric and ferrous chlorides in aqueous solution as described by Chastellain M. et al., J Colloid Interface Sci 278:353-360, 2004. The obtained black precipitate is washed several times with ultra-pure water and the remaining solid refluxed in nitric acid (10'2 M) in the
presence of iron-(lll)-nitrate. The obtained brown suspension is dialyzed against 0.01 M nitric acid for two days, and stored at 40C.
SPIONs embedded in BSA SPIONs are concentrated from the original dispersion (10 mg/ml Fe) by different methods. a) Solvent evaporation: The concentration of iron is augmented in a graduated cylinder at 9O0C up to 300 mg/ml Fe. b) Precipitation: The original SPIONs are precipitated with 1 M NaCI. The precipitated particles are centrifuged at 5000 g to separate the particles from the salt solution. The sediment is redispersed in 0.01 M nitric acid. The final concentration of SPIONs is 300 mg/ml. These dispersions are diluted to a final concentration of 5%, 10%, and 20% iron containing 20% (w/w) BSA, which is added as a powder to the dispersed particles.
SPIONs in scaffolds Polymer film preparation: 15 ml of SPIONs (7.7 mg/ml Fe) are mixed with 7.5 ml of 1 M ammonia (Fluka), 150 μl oleic acid (Fluka, cat. no. 75093) and 105 ml chloroform (Fluka). The resulting mixture is centrifuged at 3000 g for 10 minutes to transfer the SPIONs into the organic chloroform phase. The water phase is discarded and the particle dispersion concentrated to a final iron concentration of 115 mg/ml (4 ml) under the fume hood.
Nonporous films of polycaprolactone containing 5, 10, 20, 30, and 40% (w/w) iron are prepared by using a solvent-casting technique. For the preparation of a scaffold containing 40% (w/w) iron, 56 mg of polycaprolactone is dissolved in 1 ml of chloroform. Subsequently, 466 μl of the SPION dispersion described above is added and mixed. For scaffolds with lower iron content this value is adapted. This solution is spread to cover the bottom surface of a 32 mm Petri dish that is cleaned first with chloroform, followed by ethanol, and ultra-filtered deionized water. After air drying (24 h), the films are hydrated for 1 hour and then carefully peeled off the bottom of the Petri dish. Then, the resulting polymer films are air dried and stored at room temperature.
Porous films of polycaprolactone containing 5, 10, 20, 30, and 40% (w/w) iron are prepared by using a solvent-casting technique and particulate leaching technique. For the preparation of a scaffold containing 40% (w/w) iron, 56 mg of polycaprolactone is dissolved in 1 ml of chloroform. Subsequently, 466 μl of the SPION dispersion described above is added and mixed. Then sodium chloride particles of a size between 100 and 125 μm at concentrations of 70 to 90 (w/w) are added, corresponding to 217.7 and 839.3 mg,
respectively. For scaffolds with lower iron content these values are adapted. This solution is spread to cover the bottom surface of a 32 mm Petri dish that is cleaned first with chloroform, followed by ethanol, and ultra-filtered deionized water. After air drying for 24 h, the films are hydrated for 1 hour and then carefully peeled off the bottom of the Petri dish. Then the resulting polymer films are air dried and stored at room temperature.
Polycaprolactone may also be replaced by poly (DL-lactide-co-caprolactone) 40:60, poly (DL-lactide) and other copolymers.
Induction heating system setup
For the soldering experiments a system consisting of a high frequency generator (Power Controller 32/1800, Ceia, Italy) operated at a frequency of 1.8 MHz and a magnetic flux density of 40 mT is used. The generator is connected to a control unit (Power controller v2, Ceia, Italy), which sets the energy output of the system at a predefined optimum for the special coil. The alternating current is transferred on a water cooled coil consisting of a thin copper tube which induces the electromagnetic field. This coil has an outer diameter of 5.5 mm, the tube itself has a diameter of 1.5 mm. Cooling is achieved by continuous water flow through the tube. The output power is controlled by reduction of the pulse length of the electromagnetic field for lower power levels or by changing the strengths of the electromagnetic field by changing the current.
A second and custom made induction device consisting of a frequency generator, an amplifier and a resonant circuit harbouring a ferrite core has been realized. The resonant circuit is justified for maximal energy absorption in the tissue. The operating frequency is adaptable from 30 kHz to 470 MHz, and the amplifier power is 2000 W.
For the temperature feedback loop a fluoro-optical temperature sensor (FOT Lab-Kit, Luxtron, CA, USA) is used, allowing the recording of a contact temperature profile at a pickup frequency of 4 Hz. A negative feedback control consisting of a control unit (Power controller v2, Ceia, Italy) between the temperature measurement system and the high frequency generator enables a fast and constant levelling of the temperature (Figure 1).
Metallic structures as energy mediator
A platinum ring (MR) (inner diameter: 2.8 mm, wire diameter: 0.25 mm) (ELANA BV, Utrecht, The Netherlands) and a stainless steel grid (MG) (BOPP, Zurich, Switzerland) with a wire diameter: 0.065 mm, mesh opening: 0.3 mm are used as solid mediators for
conversion of the electromagnetic to thermal energy and are compared with dispersed agglomerates of SPION with particles size of 15 nm in diameter.
Solder Solder consists of 36% (w/w) of bovine serum albumin (BSA) dissolved in pure sterile water for the experiments in conjunction with the solid metal parts (MR and MG). BSA concentration is kept at 20% (w/w) in combination with SPIONs.
Teflon receptacle A teflon receptacle is used for the analysis of the temperature profiles for MR and
SPIONs. The distance from the induction coil to MR and MG is between 1.2 mm and 2.4 mm and for the SPIONs 2.4 mm defined as the distance from the centre of the measured volume (30 μl) in the receptacle to the coil.
Soldering temperature parameters
The total induction time is dependent on the time needed to reach the target temperature of 8O0C ± 50C and the holding time. A tissue soldering holding time of 60 seconds is considered suitable for tissue fusion.
Vascular tissue and tensile strength measurement
Pieces of rabbit abdominal aorta (15 x 10 mm) are used for the in vitro soldering experiments (Soltermann, Thδrigen, Switzerland). The two adventitial surfaces are soldered together with an overlapping area of 1 cm2 responsible for the connection. The tissue is placed in a custom made tissue holder made out of Perspex, enabling a constant distance of the tissue and the induction coil.
The strength of the so induced tissue connection is quantified using a tensile strength measurement setup. Both pieces of soldered tissue are fixed with surgical clamps, one of them attached to a force gauge measuring the maximum tensile strength in mN during the rupture procedure.
Induction of the MR in teflon receptacle
The heating of the MR in 30 μl of albumin solder in the teflon receptacle is tested. Temperature heating curves are analyzed in dependence of power output and distance of the induction coil to the metal parts. A maximum temperature of 1000C is reached. Induction time is 30 s.
Solder temperatures increased in dependence of power and distance during the 30 s induction time. The optimal distance for induction of the MR for tissue fusion is found to be in the range of 2 to 4 mm. The optimal range for power is found to be between 20 and 50%, always dependent on distance (distance 4 mm: 50% power, distance 2 mm: 20% power).
Induction of SPION in teflon receptacle
30 μl of SPION dispersed in 20% (w/w) albumin solder are induced in a teflon receptacle and analyzed with respect to their heating ability. 5, 10 and 20% (w/w) of SPIONs are analyzed. Distance from the coil to the nanoparticles is kept at the closest distance possible to the middle of the fluid volume of 2.4 mm, and the power output of the electromagnetic high frequency generator is set to 90% for an overall activation time of 30 s. Increasing the SPION concentration from 5%, 10% to 20% results in an increase in solder temperature.
Tissue soldering: Induction of MR and MG with vessels
Pieces of vascular tissue are adapted as described above. Between the two tissue pieces a MR as well as 30 μl of BSA solder without and with an oxidized cellulose gauze (Tabotamp, Johnson and Johnson, Switzerland) is placed. This complex is exposed to the electromagnetic field for soldering. The grid is immersed in 30 μl of solder before placing it between the two tissue pieces. Temperature is regulated with the above described feedback mechanism at 800C. Induction time is 60 s after reaching 80"C. In order to maintain this temperature over 60 seconds, the power of the electromagnetic high frequency generator is regulated by the temperature control feedback to a mean power output of 20%.
Induction of SPION with vessels
Pieces of vascular tissue are adapted as described above. 30 μl of SPION (20% w/w) dispersed in BSA are used. The induction setup needs to be adapted in order to reach sufficient induction parameters to reach the acceptable temperatures. Temperature is regulated with the above described feedback mechanism at 8O0C. Induction time is 60 s after reaching 80 °C. The power of the electromagnetic high frequency generator is set at 90%, according to the findings from the teflon receptacle studies.
Tissue soldering compared with suturing
The most constant temperature profile was recorded for the SPION tissue soldering. Tensile strength of MR, MR-cellulose, MG and SPION were 2922 ± 623, 2668 ± 176, 3692 ± 190 and 3078 ± 852 mN (n=5), respectively. Findings are reported in mean ± standard deviaton (SD). For the analysis of the tensile strength between MR, MG and SPION the ANOVA test is used. Significance is defined at a p<0.05. Further, for comparison five pairs of tissue samples, identical to those used for the soldering experiments were sutured in conventional manner. A (8-0) Prolene thread (Ethicon J&J, Spreitenbach, Switzerland) was used to accomplish interrupted suture, seven stitches were performed along the tissue edge of 1 cm. Thereafter, tensile strength of these samples were measured, too, yielding a rupture force of 2580 ± 950 nM.
Histology
Soldered tissue is fixated in formaldehyde and later embedded into methylacrylate resin over a 30 day period for slow hardening in order to perform the tissue slices. The tissue blocks are then cut with a diamond band saw with a slice thickness of 150 μm (Exakt Apparatebau, Nordersted-Hamburg, Germany). Thereafter the slices are polished down to a thickness of 50 μm. The slices are stained using haematoxylin and eosin (HE). The histological HE staining of the electromagnetically induced vessel tissue fusion using SPION demonstrates the close contact of the abdominal aorta vessel tissue pieces (Figure 2).
In vivo tests
Subcutaneous implantation of SPION-BSA-PVA solder into 10 living rats (wistar rats) is performed in order to observe eventual pathologic effects on the living body, such as those observed in the iron storage disease called haemochromatosis.This hereditary disease is characterized by improper dietary iron metabolism (making it an iron overload disorder), which causes the accumulation of iron in a number of body such as liver, kidney and pancreas. Since nanoparticles are theoretically small enough to pass the blood-brain barrier, the brain is also investigated to achieve certainty that it is not affected. MRI is performed on the rats, and iron presence is checked in the regions of interest as a mean to measure iron content variations. To crosscheck the measurements, the rats are euthanized right after MRI and histology is performed on the organs of interest. This enables a control of the measured T2* relaxation times (MRI). The resulting tissue iron content correlates with microscopical analyses of particular organs by special iron stainings.
Further information is collected about the behaviour of the film in living tissue. In order to find out how the surrounding tissue reacts to the implant, histology is performed on the implantation region.
Solder film composition was 25 % (w/w) SPION, 42 % (w/w) BSA and 8 % (w/w) water. Sample dimensions were 5 mm x 5 mm x 0.5 mm. Films were implanted subcutaneously into the neck of 8 rats; 4 of the films were then electromagnetically soldered, while 4 of them were kept in their raw state. MRI and euthanization was performed after 1 , 4, 15 and 28 days. MRI was done on one sham rat, and histology was made on two sham rats as well as on all other rats. Figure 5 shows that there are no significant changes in the presence of the SPION-BSA- PVA implant in the liver, spleen, kidney, brain and pancreas by MRI. However, a broad signal loss is achieved in the rats neck (Figure 6). Histology results prove that there is no inflammation occurring in the region of interest. Lack of presence of SPION in the region of interest is shown by staining with Prussian blue. The results prove that SPION film is relatively inert and SPIONs do not concentrate in investigated organs over a timerange of 4 weeks, and thus do not affect the function of those particular organs. In histology of the liver, a slight increase of Kupffer cells counts (macrophages of the liver) are observed, which indicates that some SPIONs are degraded.
Claims
1. Superparamagnetic iron oxide nanoparticles for use in sutureless thermal mediated tissue fusion.
2. The superparamagnetic iron oxide nanoparticles for use in sutureless thermal mediated tissue fusion according to claim 1 , wherein an alternating electromagnetic field is applied.
3. The superparamagnetic iron oxide nanoparticles for use in sutureless thermal mediated tissue fusion according to claim 1 , wherein the tissue fused is skin, musculoskeletal, visceral, vascular, or neuro-glial tissue.
4. A pharmaceutical preparation comprising superparamagnetic iron oxide nanoparticles and a biocompatible material.
5. The pharmaceutical preparation according to claim 4, wherein the biocompatible material is selected from proteins, peptides and glycopeptides of animal or human origin, and biocompatible polymers.
6. The pharmaceutical preparation according to claim 4, wherein the superparamagnetic iron oxide nanoparticles have a diameter of below 20 nm.
7. The pharmaceutical preparation according to claim 6, wherein the superparamagnetic iron oxide nanoparticles have a diameter of between 5 nm and 15 nm.
8. The pharmaceutical preparation according to claim 4, wherein the superparamagnetic iron oxide nanoparticles are coated with an organic or inorganic compound.
9. The pharmaceutical preparation according to claim 4, wherein the biocompatible material is a soldering agent.
10. The pharmaceutical preparation according to claim 9, wherein the soldering agent is albumin.
11. The pharmaceutical preparation according to claim 4, wherein the superparamagnetic iron oxide nanoparticles are embedded in a biocompatible scaffold.
12. The pharmaceutical preparation according to claim 1 1 , wherein the biocompatible scaffold is selected from polyglycolide, polylactides, polycaprolactone; di- and tri-block polymers; polyorthoesters, polyanhydrides, polyhydroxyalkanoates, polypyrroles, poly(ether ester amides), elastic shape-memory polymers; and hydrogels.
13. The pharmaceutical preparation according to claim 1 1 , wherein the biocompatible scaffold is selected from polycaprolactone, poly(DL-lactide-co-caprolactone), and poly(DL- lactide).
14. The pharmaceutical preparation according to claim 4 further comprising bioactive molecules.
15. The pharmaceutical preparation according to claim 14, wherein the bioactive molecules are selected from vascular endothelial growth factor (VEGF), nerve growth factor (NGF), brain derived neurothropic factor (BDNF), glial derived neurothropic factor (GDNF)1 erythropoietin (EPO), fibroblast growth factor (FGF), transforming growth factor (TGF), insulin-like growth factor (IGF), and subgroups of the mentioned compounds.
16. Use of superparamagnetic iron oxide nanoparticles for the manufacture of a medicament for use in tissue fusion with an alternating electromagnetic field.
17. A method of tissue fusion wherein superparamagnetic iron oxide nanoparticles dispersed in a biocompatible material are heated by application of an alternating electromagnetic field.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07007600 | 2007-04-13 | ||
EP07007600.5 | 2007-04-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008125259A2 true WO2008125259A2 (en) | 2008-10-23 |
WO2008125259A3 WO2008125259A3 (en) | 2009-07-30 |
Family
ID=39539577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/002796 WO2008125259A2 (en) | 2007-04-13 | 2008-04-09 | Super paramagnetic iron oxide nanoparticle coupled tissue soldering |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008125259A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009002768A1 (en) | 2009-04-30 | 2010-11-04 | Celon Ag Medical Instruments | Material layer and electrosurgical system for electrosurgical tissue fusion |
WO2011006937A1 (en) | 2009-07-16 | 2011-01-20 | Celon Ag Medical Instruments | Anastomosis ring and anastomosis ring assembly |
WO2014135566A1 (en) * | 2013-03-08 | 2014-09-12 | Aesculap Ag | Tissue fusion agent |
DE102016218401A1 (en) | 2016-09-23 | 2018-03-29 | Olympus Winter & Ibe Gmbh | An electrosurgical system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005058143A2 (en) * | 2003-12-15 | 2005-06-30 | Kevin Marchitto | Electromagnetic treatment of tissues and cells |
WO2006116403A2 (en) * | 2005-04-22 | 2006-11-02 | Intematix Corporation | Intracellular thermal ablation using nano-particle electron spin resonance heating |
WO2006125452A1 (en) * | 2005-05-23 | 2006-11-30 | Universite De Geneve | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant |
-
2008
- 2008-04-09 WO PCT/EP2008/002796 patent/WO2008125259A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005058143A2 (en) * | 2003-12-15 | 2005-06-30 | Kevin Marchitto | Electromagnetic treatment of tissues and cells |
WO2006116403A2 (en) * | 2005-04-22 | 2006-11-02 | Intematix Corporation | Intracellular thermal ablation using nano-particle electron spin resonance heating |
WO2006125452A1 (en) * | 2005-05-23 | 2006-11-30 | Universite De Geneve | Injectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant |
Non-Patent Citations (2)
Title |
---|
GUPTA A K ET AL: "Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 26, no. 18, 1 June 2005 (2005-06-01), pages 3995-4021, XP025280559 ISSN: 0142-9612 [retrieved on 2005-06-01] * |
NEUBERGER T ET AL: "Superparamagnetic nanoparticles for biomedical applications: Possibilities and limitations of a new drug delivery system" JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 293, no. 1, 1 May 2005 (2005-05-01), pages 483-496, XP025365286 ISSN: 0304-8853 [retrieved on 2005-05-01] * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102009002768A1 (en) | 2009-04-30 | 2010-11-04 | Celon Ag Medical Instruments | Material layer and electrosurgical system for electrosurgical tissue fusion |
US9370344B2 (en) | 2009-04-30 | 2016-06-21 | Olympus Winter & Ibe Gmbh | Method of fusing layers of biological tissue |
WO2011006937A1 (en) | 2009-07-16 | 2011-01-20 | Celon Ag Medical Instruments | Anastomosis ring and anastomosis ring assembly |
US9050088B2 (en) | 2009-07-16 | 2015-06-09 | Olympus Winter & Ibe Gmbh | Anastomosis ring and anastomosis ring arrangement |
DE102009027813A1 (en) | 2009-07-17 | 2011-01-27 | Celon Ag Medical Instruments | Anastomosis ring and anastomosis ring arrangement |
WO2014135566A1 (en) * | 2013-03-08 | 2014-09-12 | Aesculap Ag | Tissue fusion agent |
US10456507B2 (en) | 2013-03-08 | 2019-10-29 | Aesculap Ag | Tissue fusion agent |
DE102016218401A1 (en) | 2016-09-23 | 2018-03-29 | Olympus Winter & Ibe Gmbh | An electrosurgical system |
WO2018055046A1 (en) | 2016-09-23 | 2018-03-29 | Olympus Winter & Ibe Gmbh | Electrosurgical system |
Also Published As
Publication number | Publication date |
---|---|
WO2008125259A3 (en) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mondal et al. | Magnetic hydroxyapatite: a promising multifunctional platform for nanomedicine application | |
Omidinia‐Anarkoli et al. | An injectable hybrid hydrogel with oriented short fibers induces unidirectional growth of functional nerve cells | |
Lin et al. | In vitro feasibility study of the use of a magnetic electrospun chitosan nanofiber composite for hyperthermia treatment of tumor cells | |
KR101627043B1 (en) | Method for preparing magnetic scaffold including nanoparticle with functionalized surface for bone regeneration and a magnetic scaffold obtained thereby | |
Piñeiro et al. | Iron oxide based nanoparticles for magnetic hyperthermia strategies in biological applications | |
Rodriguez-Arco et al. | Biocompatible magnetic core–shell nanocomposites for engineered magnetic tissues | |
Li et al. | Imaging guided photothermal therapy using iron oxide loaded poly (lactic acid) microcapsules coated with graphene oxide | |
Samal et al. | Biomimetic magnetic silk scaffolds | |
EP3277328B1 (en) | Ferromagnetic particles bound to polymeric implants | |
Samal et al. | Multilayered magnetic gelatin membrane scaffolds | |
US20170232157A1 (en) | Tissue integrating materials for wound repair | |
US9833415B2 (en) | 3D tumor targeting with diamagnetic repulsion | |
US20030236518A1 (en) | Method and device for anastomoses | |
WO2008039521A2 (en) | Method for modifying a medical implant surface for promoting tissue growth | |
WO2008125259A2 (en) | Super paramagnetic iron oxide nanoparticle coupled tissue soldering | |
JP2007520275A (en) | Medical devices visible under magnetic resonance images | |
Ali et al. | Hemostasis disorders caused by polymer coated iron oxide nanoparticles | |
Savva et al. | Fabrication, characterization, and evaluation in drug release properties of magnetoactive poly (ethylene oxide)–poly (l-lactide) electrospun membranes | |
CN107050452A (en) | A kind of aptamer modified magnetic nanoparticle and its preparation method and application | |
Lee et al. | Remote induction of in situ hydrogelation in a deep tissue, using an alternating magnetic field and superparamagnetic nanoparticles | |
Zhong et al. | Electrospun magnetic nanofibre mats–A new bondable biomaterial using remotely activated magnetic heating | |
JP2014506813A (en) | Implantable or insertable medical device capable of MRI detection having a coating containing paramagnetic ions and method for manufacturing the same | |
Chen et al. | Preparation and characterization of 3D porous conductive scaffolds with magnetic resonance enhancement in tissue engineering | |
He et al. | Guidable GNR-Fe3O4-PEM@ SiO2 composite particles containing near infrared active nanocalorifiers for laser assisted tissue welding | |
Sánchez et al. | Heating capacity and biocompatibility of Pluronic-coated manganese gallium ferrites for magnetic hyperthermia treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08735109 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08735109 Country of ref document: EP Kind code of ref document: A2 |